Episode 109: AB126, Exosomes, and Cerebroprotection for Stroke

Author(s):

Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Stephen From. [LISTEN TIME: 22 minutes]

Stephen From

Credit: Aruna Bio

Episode 109 of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

Episode 109, "AB126, Exosomes, and Cerebroprotection for Stroke" features a conversation with Stephen From, chief executive officer of Aruna Bio, who sat down to discuss the company's investigational exosome candidate AB126 and its upcoming phase 1b/2a trial in patients with ischemic stroke. He discussed the mechanism of action of the therapy, the advantages of its anti-inflammatory and neuroprotective properties, and how it will be used with other stroke treatments. Furthermore, he gave insight on the complexities with conducting stroke trials and improving neurodegeneration in poststroke patients.

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences^®. Check out new content and shows every day, only at medicalworldnews.com

EPISODE BREAKDOWN

1:00 – Overviewing phase 1b/2a trial
7:05 – Mechanism of action of AB126
11:15 – Neurology News Minute
13:45 – Role of AB126 in stroke treatment landscape
17:50 – Challenges with repairing neurodegeneration in stroke

Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below: